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(250 mg/m2) intravenous infusion of cetuximab in Cet group, 
or a biweekly (500 mg/m2 on day 1) or weekly (250 mg/m2) 
intravenous infusion of cetuximab followed by irinotecan 
(150 mg/m2) in CetI group. Propensity score adjustment was 
used to achieve balance in the observational arm.
Results Data from a total of 29 patients (10 in Cet group, 
19 in CetI group) were analyzed. Crude median progres-
sion-free survival time was 2.9 months in the Cet group 
and 2.5 months in the CetI group. Crude disease control 
rates were 55.6% in the Cet group and 47.4% in the CetI 
group. After a median follow-up of 43 months, the crude 
median overall survival was 8.0 months in the Cet group 
and 7.6 months in the CetI group. Cetuximab-based treat-
ment did not markedly increase any characteristic toxicity 
and was generally well tolerated. Propensity score analyses 
adjusted for performance status and number of metastases 
showed comparable results with the crude results.
Conclusion Cetuximab-based treatment seemed to ben-
efit patients with chemotherapy-resistant, refractory KRAS 
G13D-mutated mCRC. Our results might support the 
administration of cetuximab-based treatment for KRAS-
mutant mCRC and would be able to provide treatment flex-
ibility in this setting.
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Introduction
Colorectal cancer (CRC) is the third-most common malig-
nant disease and one of the most frequent causes of can-
cer-related death worldwide [1]. Complete resection is 
essential for the cure of CRC. However, metastatic CRC 
(mCRC) cannot be cured by surgical resection alone, and 
the prognosis of such patients is poor [2, 3].
Abstract 
Purpose This study investigated the efficacy and safety of 
cetuximab-based treatment in patients with chemotherapy-
resistant refractory mCRC with KRAS G13D mutation.
Patients and methods An assessment of the efficacy and 
safety of cetuximab-based treatment was performed in an 
observation-enriched randomized controlled study compar-
ing the cetuximab alone group (Cet group) and the combi-
nation of cetuximab and irinotecan group (CetI group) for 
KRAS G13D-mutated mCRC in Japan. In this study, the 
patients received a biweekly (500 mg/m2 on day 1) or weekly 
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Significant advances in the treatment of mCRC have 
been achieved by the addition of molecular targeting agents 
to standard mCRC chemotherapy. Cetuximab is the first 
chimeric human-mouse monoclonal antibody of immu-
noglobulin G1 (IgG1) subclass directed against epider-
mal growth factor receptor (EGFR) [4, 5]. Cetuximab has 
been shown to be effective in the treatment of mCRC when 
administered either as monotherapy or in combination with 
other chemotherapeutic agents [6, 7]. However, retrospec-
tive studies and prospective randomized phase III studies 
of mCRC indicated that mCRC patients with KRAS codon 
12 or 13 mutations do not benefit from cetuximab [8]. The 
health authorities in Europe, the US, and Japan have there-
fore recommended compulsory KRAS mutation testing 
[9, 10]. In this respect, patients with KRAS codon 12 or 
KRAS codon 13 mutated tumors cannot receive cetuximab 
in Europe or the US. Although standard cytotoxic chemo-
therapy and/or bevacizumab are typically used for mCRC 
treatment, no valid and effective treatment for refractory 
mCRC patients with mutations of KRAS either in codon 12 
or 13 has yet been established. In this regard, the develop-
ment of a treatment for such cases is imperative to improve 
the outcome of these mCRC patients.
Recently, De Roock et al. [11] investigated the asso-
ciation between KRAS mutation status (G13D vs. other 
KRAS mutations) and response and survival in a pooled 
data set of 579 patients with chemotherapy-refractory 
CRC treated with cetuximab. They found that administra-
tion of cetuximab was associated with longer overall and 
progression-free survival among patients with chemo-
therapy-refractory CRC with G13D-mutated tumors than 
with other KRAS-mutated tumors. Furthermore, in vitro 
experiments revealed that cancer cells with KRAS codon 
13 mutation had a weaker level of resistance to apoptosis 
than those with KRAS codon 12 mutations [12]. However, 
these findings were obtained from retrospective studies 
or subgroup analyses. Therefore, a prospective validation 
study was warranted to confirm those findings. On the other 
hand, the randomized phase II BOND study (Cetuximab 
Monotherapy and Cetuximab plus Irinotecan in Irinotecan-
Refractory Metastatic Colorectal Cancer) demonstrated 
significant improvement in response rate and progression-
free survival with the addition of irinotecan to cetuximab 
in the refractory setting in molecularly unselected patients 
whose disease had progressed on irinotecan. According 
to the Bond study, we estimated synergy effects between 
cetuximab and irinotecan or response to irinotecan rechal-
lenge despite prior progression on that drug.
To optimize mCRC patients’ treatment options, this ran-
domized phase II study was designed with the aim of evalu-
ating the efficacy of cetuximab and the additional effect of 
irinotecan on cetuximab-based therapy in mCRC patients 
with a mutation in KRAS codon G13D.
Materials and methods
Study design
This was a multicenter, open-label, prospective phase II 
study investigating the efficacy and safety of cetuximab 
and irinotecan plus cetuximab in patients with chemo-
refractory mCRC with mutation at KRAS codon G13D. 
The study data and informed consent were obtained in 
accordance with the Declaration of Helsinki, and the study 
protocol was approved by the Ethics Review Board of each 
institution.
The study design was an observation-enriched rand-
omized controlled design. During the informed consent 
process, each patient selected whether they wanted to join 
the observation arm or randomization arm if they accepted 
the trial participation. If patients chose the observation 
arm, they picked the study treatment (irinotecan alone or 
irinotecan plus cetuximab) they wanted to be in. Other-
wise, they were centrally randomized to irinotecan alone 
or irinotecan plus cetuximab with a minimization tech-
nique (stratification factors were performance status and 
institution).
Patients
Patients were eligible if they were ≥20 years of age and 
had histologically confirmed mCRC; already received 
first-line chemotherapy for mCRC; a known G13D 
KRAS mutation status; measurable disease as assessed 
by computed tomography or magnetic resonance imag-
ing according to Response Evaluation Criteria in Solid 
Tumors (RECIST); an Eastern Cooperative Oncology 
Group performance status ≤1; and adequate hepatic, 
renal, and bone marrow function [white blood cell 
(WBC) count ≥3000 and ≤12,000/mm3, neutrophil 
count ≥1500/mm3, platelet count ≥100,000/mm3, GOT 
and GPT ≤100 U/l, total bilirubin <1.5 mg/dl, creatinine 
<1.5 mg/dl, and normal ECG]. Patients were ineligible 
if they had a history of previous exposure to EGFR-tar-
geted therapy and/or uncontrolled severe organ/metabolic 
dysfunction.
Study treatment
The enrolled patients started protocol treatment within 
14 days after registration: a biweekly intravenous (IV) infu-
sion of cetuximab (500 mg/m2 on day 1) or a weekly IV 
infusion of cetuximab (an initial intravenous infusion of 
400 mg/m2 with subsequent weekly doses of 250 mg/m2) 
(Cet group); a biweekly IV infusion of irinotecan (150 mg/
m2 on day 1) plus a biweekly IV infusion of cetuximab 
(500 mg/m2 on day 1) or a weekly IV infusion of cetuximab 
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(an initial intravenous infusion of 400 mg/m2 with subse-
quent weekly doses of 250 mg/m2) (CetI group).
KRAS and BRAF mutations
DNA was extracted from formalin-fixed paraffin-embedded 
tumor tissues. Mutation of KRAS at codon 13 was detected 
by direct sequencing, as described previously [13, 14].
Endpoints
The primary endpoint was progression-free survival (PFS). 
The PFS of patients without disease progression before the 
end of the study was censored at the last on-study tumor 
assessment date at which the patient was considered to be 
progression-free. PFS was defined as the number of days 
between the enrollment and the first on-study assessment of 
disease progression (PD) or any cause of death.
The secondary endpoints were the disease control rate, 
overall survival (OS), and the safety of the combination 
therapy. The RECIST 1.1 criteria were applied subse-
quently to assess and confirm the overall response. A radio-
logic assessment was performed at baseline, every 8 weeks 
during the first 6 months of the study, and every 12 weeks 
thereafter until PD. The OS was defined as the number 
of days between the enrollment and any cause of death. 
Patients who did not die were censored at the last follow-up 
date. Adverse events were collected throughout the study 
period. All adverse events recorded were graded according 
to the Common Terminology Criteria for Adverse Events 
version 4.0.
Statistical analyses
For the crude analysis, we analyzed all patients who 
enrolled in the trial without statistical adjustments. All 
summary statistics on time-to-event variables were calcu-
lated according to the Kaplan–Meier methods. The 95% 
confidence intervals (CIs) for median time-to-event and the 
time-specific incidence rate were constructed using Green-
wood’s formula and Brookmeyer and Crowley’s method, 
respectively. The Cox proportional hazard model was used 
to estimate the hazard ratio (HR) and its 95% CI between 
the Cet group and CetI group.
Propensity score was used to adjust the unbalance of 
prognostic factor between Cet group and CetI group in 
the observation arm to combine results of the randomiza-
tion arm with the observation arm. Propensity score was 
estimated using the logistic regression model. The vari-
able used for the logistic model was selected based on the 
standardized difference between two groups. Using the sta-
bilized inverse propensity score as weight, we created the 
pseudo-population using the total patients of observation 
arm as the standard population. A stratified analysis was 
used to summarize the results from randomization arm and 
observation arm.
The sample size was determined only for the randomi-
zation group. Assuming an absolute difference in 6 month 
PFS rate of ≥26% between the C group and CI group, 15 
patients for each group were needed to observe improved 
treatment with 95% probability. We planned to enroll 
patients in the observation arm until the target sample sizes 
in the randomization arm were achieved.
Results
Patients’ characteristics
From July 2012 to May 2015, 43 institutions collaborated 
with the G13D-study, and 33 patients were registered from 
23 institutions. Four patients did not have KRAS G13D 
mutations. Accordingly, 29 patients were defined as eligi-
ble for this study. Figure 1 shows the CONSORT diagram. 
The intention-to-treat population consisted of 29 patients. 
A safety analysis was carried out on those 29 patients who 
received at least 1 dose of any component of the study 
treatment. The patients’ clinical characteristics at base-
line are shown (Table 1). The median age of the patients 
was 69 years (range 37–83 years). In the first-line chemo-
therapy, 16 patients received bevacizumab and chemo-
therapy and 4 patients received irinotecan-based chemo-
therapy. Twelve patients (41.4%) had metastatic lesions in 
1 organ, and 17 patients (58.6%) had metastatic lesions in 
more than 1 organ. As expected, hepatic metastases were 
the most common, with lesions detected in 17 patients 
(58.6%).
Fig. 1  CONSORT diagram of the present study
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Efficacy
After a median follow-up of 43 months, the crude median 
PFS was 2.9 months (95% CI 0.7–4.3) in the Cet group and 
2.5 months (95% CI 2.1–3.5) in the CetI group (Fig. 2), 
which was not statically different (HR = 0.69, 95% CI 
0.30–1.59, p = 0.380). In addition, the crude median OS 
was 8.0 months (95% CI 1.9–14.1) in the Cet group and 
7.6 months (95% CI 3.9–11.5) in the CetI group (Fig. 3), 
which was not statically different (HR = 0.87, 95% CI 
0.39–1.95, p = 0.741). In addition, 6-month progression-
free survival rates were 10% (95% CI 0.5–35.8%) in Cet 
group and 0% in CetI group. There was not significantly 
difference between two groups (p = 0.375).
The efficacy data are summarized in Table 2. The dis-
ease control rate (DCR) was 60% (95% CI 26–88) in the 
Cet group and 47% (95% CI 24–71) in the CetI group, 
which was not statically different (p = 0.800). The best 
Table 1  Patient characteristics
ECOG Eastern Cooperative Oncology Group
Characteristics Total (n = 29) Cetuximab alone (n = 10) Cetuximab + CPT-11 (n = 19)
No. of patients (%) No. of patients (%) No. of patients (%)
Gender
 Male 21 (72.4) 8 (80.0) 13 (68.4)
 Female 8 (27.6) 2 (22.2) 6 (31.6)
Age (years)
 Median 69 69 69
 Range (37–83) (58–80) (37–83)
ECOG performance status
 0 19 (65.5) 4 (40.0) 15 (78.9)
 1 10 (34.5) 6 (60.0) 4 (21.1)
Cancer location
 Colon 16 (55.2) 7 (70.0) 9 (47.4)
 Rectum 13 (44.8) 3 (30.0) 10 (52.6)
Primary site resection
 No 19 (65.5) 6 (60.0) 13 (68.4)
 Yes 10 (34.5) 4 (40.0) 6 (31.6)
Previous chemotherapy therapy line
 1st, 2nd line 25 (86.2) 8 (80.0) 17 (89.5)
 3rd, 4th line 4 (13.8) 2 (20.0) 2 (10.5)
No. of organs with metastases
 1 12 (41.4%) 4 (40.0) 8 (42.1)
 2 9 (31.0%) 5 (50.0) 4 (21.1)
 >3 8 (27.6%) 1 (10.0) 7 (36.8)
Metastases site
 Liver 17 5 (50.0) 12 (63.2)
 Lung 16 7 (70.0) 9 (47.4)
 Lymph node 10 3 (30.0) 7 (36.8)
Fig. 2  Progression-free survival in patients treated with cetuximab 
alone versus cetuximab + irinotecan
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response is shown in Fig. 4. In addition, the DCR was 41% 
in the patients who had hepatic metastases (40% in the Cet 
group and 42% in the CetI group), 50% in the patients who 
had lung metastases (57% in the Cet group and 44% in the 
CetI group), and 50% in the patients who had lymphatic 
metastases (100% in the Cet group and 29% in the CetI 
group). There were no differences in the DCR by meta-
static organ.
Efficacy results after adjustment using propensity score
In the observation arm, performance status and number of 
metastasis showed discrepancy based on the standardized 
difference between Cet group and CetI group. Thus, we 
estimated propensity score using performance status and 
number of metastasis as covariates. After adjustment using 
propensity score, the HR for PFS was 1.15 (95% CI 0.45–
2.93) and there was no statistical difference between Cet 
and CetI group (p = 0.765). OS was also similar between 
two groups (HR = 1.03; 95% CI 0.44–2.41; p = 0.950).
Treatment compliance and safety
The median course of the study treatment was 2.6 months 
(range 2.2–3.4). The median course of the study treatment 
was 2.8 months (95% CI 0.7–4.7) in the Cet group and 
2.5 months (95% CI 2.2–3.5) in the CetI group, which was 
not statically different. Patients achieving a relative dose 
intensity >80% for each drug are also shown.
Adverse events (AEs) of grade 3 or 4 occurring in at 
least 34.5% (10/29 patients) of the patients are summarized 
(Table 3). The most common grade 3 or 4 AEs were neu-
tropenia, anorexia, and fatigue. Although the incidence of 
neutropenia was higher in the CetI group than in the Cet 
group, the rates of the other adverse events were similar 
between the two groups.
Fig. 3  Overall survival in the patients treated with cetuximab alone 
versus cetuximab + irinotecan
Table 2  Efficacy data
PFS progression-free survival, OS overall survival, CI confidence interval
Parameter All cases Cetuximab alone (n = 10) Cetuximab + CPT-11 (n = 19) p value
Best overall response rate
 Complete response 0 0 0
 Partial response 0 0 0
 Stable disease 15 6 9
 Progressive disease 12 2 10
 Not assessable 2 2 0
 Disease control rate 51.7% 60.0% 47.4% 0.800
Median PFS (months) 2.6 2.9 2.5 0.380
 95% CI 2.1–3.3 0.7–4.3 2.1–3.5
 Progression events 29 10 19
 Censored 0 0 0
Median OS (months) 7.6 8.0 7.6 0.741
 95% CI 4.8–11.5 1.9–14.1 3.9–11.5
 Deaths 26 10 16
 Censored 3 0 3
 1-year survival rate 27.9 30.0 26.3
 95% CI 9.9–41.1 7.1–57.8 8.6–48.4
 2-year survival rate 8.0 10 6.6
 95% CI 1.4–22.3 0.6–35.8 0.4–25.6
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Discussion
This study was a prospective clinical trial to investigate 
the efficacy and safety of cetuximab-based treatment in 
patients with chemotherapy-resistant, refractory mCRC 
with KRAS G13D mutation. The present study showed 
that the treatment effects were similar to those in patients 
with KRAS wild-type tumors. Cetuximab-based treatment 
seemed to benefit patients with chemotherapy-resistant, 
refractory KRAS G13D-mutated mCRC, despite their 
mutation.
The median progression-free survival (PFS) was 
2.9 months (95% CI 0.7–4.3) in the Cet group and 
2.5 months (95% CI 2.1–3.5) in the CetI group in the pre-
sent study. Similar PFS was observed, regardless of the 
treatment regimen. These results were similar to those of 
previous phase reports regarding the administration of 
cetuximab-based treatment in patients with refractory 
mCRC with KRAS G13D mutation. There have been two 
reports evaluating PFS in this setting. Bando et al. [15] ret-
rospectively investigated the relationship between KRAS 
status and cetuximab efficacy among Japanese patients. In 
their study, 7 patients with refractory mCRC with KRAS 
G13D mutation were treated by a cetuximab + irinotecan 
regimen. No statistically significant differences in the PFS 
were observed between KRAS p.G13D-mutant and other 
mutant tumors. In addition, De Roock et al. [11] studied the 
association of KRAS G13D mutation with outcome after 
cetuximab treatment in a pooled data set of 579 patients 
with chemotherapy-refractory metastatic CRC treated with 
cetuximab with or without chemotherapy. They found that 
the patients with G13D-mutated tumors (n = 32) treated 
Fig. 4  Best response of the present study
Table 3  Relevant adverse 
events
ALP alkaline phosphatase, Bil bilirubin
Adverse event All cases (Grade 3/4) Cetuximab alone (Grade 
3/4)
Cetuximab + CPT-11 
(Grade 3/4)
Number of patients (%) Number of patients (%) Number of patients (%)
Hematological
 Leukopenia 1 3.4 0 0 1 5.3
 Neutropenia 4 13.8 0 0 4 21.2
 Anemia 2 6.8 1 10.0 1 5.3
 Thrombocytopenia 0 0 0 0 0 0
No hematological
 Elevated ALP 2 6.8 1 10.0 1 5.3
 Elevated serum Bil 0 0 0 0 0 0
 Elevated creatine 0 0 0 0 0 0
 Stomatitis 0 0 0 0 0 0
 Nausea/vomiting 1 3.4 0 0 1 5.3
 Diarrhea 1 3.4 0 0 1 5.3
 Rash 0 0 0 0 0 0
 Paronychia 0 0 0 0 0 0
 Anorexia 4 13.8 2 20.0 2 10.6
 Fatigue 4 13.8 1 10.0 3 15.9
 Infusion related reaction 0 0 0 0 0 0
 Paresthesia 0 0 0 0 0 0
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with cetuximab had longer PFS than the patients with 
KRAS-mutated tumors in other locations (median 4.0 
[95% CI 1.9–6.2] months vs. 1.9 [95% CI 1.8–2.8] months; 
adjusted HR = 0.51 [95% CI 0.32–0.81; p = 0.004]).
The PFS in the present study was slightly shorter than 
in previous reports, possibly due to differences in the study 
design, patient backgrounds, and details of treatment. In 
contrast, there was no significant difference in the PFS 
between the Cet group and the CetI group in the present 
study (HR = 0.69, 95% CI 0.30–1.59, p = 0.380). Similar 
results were observed in a recent phase II study; Segelov 
et al. [16] assessed cetuximab monotherapy and cetuximab 
plus irinotecan in patients with molecularly selected (G13D 
mutation) chemotherapy-refractory mCRC in a randomized 
phase II trial (ICECREAM study). They found that PFS in 
patients with KRAS G13D-mutated mCRC did not signifi-
cantly differ between those treated with cetuximab mono-
therapy and those treated with combined cetuximab and 
irinotecan. Moreover, when comparing the present study 
results and ICECREAM trial results, the 6-month PFS of 
cetuximab monotherapy was similar although the number 
of patients was small. In the present study, we estimated 
synergy effects between cetuximab and irinotecan or 
response to irinotecan rechallenge despite prior progression 
on that drug in this setting. However, these effects were not 
observed in the present study. However, De Roock et al. 
reported conflicting findings that the median PFS was 1.8 
(95% CI 1.7–11.0) months in the cetuximab monotherapy 
group (n = 10) versus 4.1 (95% CI 2.8–6.9) months in 
the cetuximab plus chemotherapy group (n = 22). These 
results might suggest a synergetic effect of cytotoxic agents 
and targeted agents or persistent chemotherapy sensitivity 
[16]. Future studies should focus on this issue.
The crude median OS was 8.0 months (95% CI 1.9–
14.1) in the Cet group and 7.6 months (95% CI 3.9–11.5) 
in the CetI group, which was not statically different 
(HR = 0.87, 95% CI 0.39–1.95, p = 0.741). A similar 
HR was observed in the ICECREAM study (HR = 0.95 
[95% CI 0.53–1.68]). Furthermore, the disease control rate 
(DCR) was 60% in the Cet group and 47.4% in the CetI 
group. The ICECREAM study showed that the response 
and stable disease rates were 0 and 58% for cetuximab 
monotherapy and 9 and 70% for cetuximab + irinotecan 
combination treatment, respectively [16].
Although 35% of patients experienced grade 3/4 AE in 
our study and hematological toxicities were slightly higher 
with combination therapy, the incidence of the worse toxic-
ities in the combination was within the previously reported 
ranges. The cetuximab-based treatment was generally well 
tolerated, and there was no evidence suggesting that cetux-
imab-based treatment increased the frequency or severity 
of characteristic toxicities. The rate of grade 3/4 AE was 
44–59% in the ICECREAM study [16].
One important limitation of the present study is the lack 
of pertaining to comparison with outcomes of previous 
standard regimen. The standard second-line treatment was 
cytotoxic chemotherapy, such as FORFOX or FORFIRI, 
with/without bevacizumab typically used for refractory 
mCRC patients with mutations of KRAS in codon 13 muta-
tion. Moreover, the standard third-line treatment was cyto-
toxic chemotherapy for refractory mCRC patients with 
mutations of KRAS in codon 13 mutation. However, the 
patient’s background and treatment were quite different 
between the present study and the previous studies. There-
fore, it is difficult to draw the definitive conclusions from 
the present study.
In conclusion, cetuximab-based treatment seemed to 
benefit patients with chemotherapy-resistant, refractory 
mCRC with KRAS G13D mutation. In addition, the pre-
sent study showed that the cetuximab-based treatment 
was well tolerated and had a manageable safety profile 
for chemo-refractory mCRC with KRAS G13D mutation. 
Our results might support the administration of cetuximab-
based treatment for mCRC with KRAS mutation in codon 
G13D despite their mutation, providing treatment flexibil-
ity in this setting.
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